Detalles de la búsqueda
1.
Azaindole N-methyl hydroxamic acids as HIV-1 integrase inhibitors-II. The impact of physicochemical properties on ADME and PK.
Bioorg Med Chem Lett
; 20(24): 7429-34, 2010 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21036042
2.
(3aS,7aS)-5-[(S)-3,3,3-Trifluoro-2-meth-oxy-2-phenyl-propano-yl]-2,3,4,5,6,7-hexa-hydro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one monohydrate.
Acta Crystallogr Sect E Struct Rep Online
; 66(Pt 1): o175-6, 2009 Dec 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-21580061
3.
Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497).
J Med Chem
; 61(3): 650-665, 2018 02 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29211475
4.
Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.
J Med Chem
; 57(11): 4720-44, 2014 Jun 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-24819116
5.
Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib.
J Med Chem
; 57(4): 1170-87, 2014 Feb 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-24432909
6.
Synthesis of aryl ethers via a sulfonyl transfer reaction.
Org Lett
; 14(15): 3886-9, 2012 Aug 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-22799458
7.
Design and synthesis of novel N-hydroxy-dihydronaphthyridinones as potent and orally bioavailable HIV-1 integrase inhibitors.
J Med Chem
; 54(9): 3393-417, 2011 May 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-21446745
Resultados
1 -
7
de 7
1
Próxima >
>>